Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
72.5
USD
|
-1.60%
|
|
-3.07%
|
-8.91%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,805
|
3,042
|
1,424
|
3,349
|
3,766
|
3,443
|
-
|
-
|
Enterprise Value (EV)
1 |
3,605
|
2,907
|
1,387
|
3,243
|
3,558
|
3,397
|
3,371
|
2,851
|
P/E ratio
|
-51.4
x
|
-29.4
x
|
-10.9
x
|
-16.8
x
|
-15.1
x
|
-15
x
|
-190
x
|
12.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
66.9
x
|
13.9
x
|
9.15
x
|
5.13
x
|
3.08
x
|
EV / Revenue
|
-
|
-
|
-
|
64.8
x
|
13.1
x
|
9.03
x
|
5.02
x
|
2.55
x
|
EV / EBITDA
|
-
|
-29.3
x
|
-11.1
x
|
-18.5
x
|
-15.8
x
|
-17
x
|
66.5
x
|
7.9
x
|
EV / FCF
|
-77.7
x
|
-37
x
|
-12.8
x
|
-27.7
x
|
-24.4
x
|
-17.8
x
|
-74.9
x
|
14.9
x
|
FCF Yield
|
-1.29%
|
-2.7%
|
-7.83%
|
-3.61%
|
-4.09%
|
-5.61%
|
-1.34%
|
6.71%
|
Price to Book
|
21.4
x
|
26.8
x
|
90.9
x
|
30.6
x
|
19.7
x
|
113
x
|
18.5
x
|
5.21
x
|
Nbr of stocks (in thousands)
|
36,809
|
37,344
|
37,692
|
43,426
|
47,320
|
47,496
|
-
|
-
|
Reference price
2 |
103.4
|
81.47
|
37.78
|
77.13
|
79.59
|
72.50
|
72.50
|
72.50
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
50.04
|
270.6
|
376.2
|
671.5
|
1,117
|
EBITDA
1 |
-
|
-99.12
|
-124.6
|
-175.4
|
-225
|
-200.1
|
50.66
|
361
|
EBIT
1 |
-67.25
|
-99.14
|
-124.7
|
-179.8
|
-231.8
|
-212.1
|
17.9
|
382.3
|
Operating Margin
|
-
|
-
|
-
|
-359.33%
|
-85.67%
|
-56.38%
|
2.67%
|
34.22%
|
Earnings before Tax (EBT)
1 |
-68.48
|
-101.7
|
-130.4
|
-187.1
|
-238.3
|
-223
|
-9.789
|
342.3
|
Net income
1 |
-68.35
|
-102.9
|
-130.4
|
-187.1
|
-239.2
|
-233.3
|
-23.22
|
291
|
Net margin
|
-
|
-
|
-
|
-373.99%
|
-88.41%
|
-62%
|
-3.46%
|
26.05%
|
EPS
2 |
-2.010
|
-2.770
|
-3.470
|
-4.600
|
-5.270
|
-4.830
|
-0.3808
|
5.759
|
Free Cash Flow
1 |
-46.39
|
-78.5
|
-108.5
|
-117.2
|
-145.7
|
-190.7
|
-45.03
|
191.2
|
FCF margin
|
-
|
-
|
-
|
-234.25%
|
-53.83%
|
-50.68%
|
-6.71%
|
17.12%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
52.97%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
65.71%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
8.82
|
16.85
|
24.37
|
94.58
|
46.7
|
57.79
|
71.53
|
75
|
86.85
|
99.98
|
116.3
|
117.8
|
142.2
|
EBITDA
1 |
-
|
-
|
-
|
-40.77
|
-58.22
|
-
|
-
|
-
|
-96.53
|
-
|
-63.25
|
-56.65
|
-51.46
|
-
|
-
|
EBIT
1 |
-32.61
|
-38.29
|
-39.18
|
-42.45
|
-59.92
|
-6.374
|
-65.06
|
-62.12
|
-98.27
|
-67.28
|
-60.72
|
-49.23
|
-36.55
|
-37.47
|
-23.46
|
Operating Margin
|
-
|
-
|
-444.24%
|
-252.02%
|
-245.85%
|
-6.74%
|
-139.31%
|
-107.49%
|
-137.39%
|
-89.7%
|
-69.92%
|
-49.24%
|
-31.44%
|
-31.82%
|
-16.5%
|
Earnings before Tax (EBT)
1 |
-33.98
|
-39.63
|
-41.44
|
-44.82
|
-61.24
|
-8.638
|
-67.79
|
-62.88
|
-98.98
|
-68.36
|
-63.09
|
-51.59
|
-39.17
|
-40.8
|
-26.13
|
Net income
1 |
-33.98
|
-39.63
|
-41.44
|
-44.82
|
-61.24
|
-11.22
|
-67.17
|
-62.2
|
-98.65
|
-68.36
|
-63.56
|
-53.33
|
-42.32
|
-40.8
|
-26.13
|
Net margin
|
-
|
-
|
-469.84%
|
-266.08%
|
-251.28%
|
-11.86%
|
-143.83%
|
-107.62%
|
-137.91%
|
-91.14%
|
-73.18%
|
-53.34%
|
-36.4%
|
-34.65%
|
-18.38%
|
EPS
2 |
-0.9000
|
-1.030
|
-1.060
|
-1.070
|
-1.410
|
-0.2600
|
-1.540
|
-1.320
|
-2.080
|
-1.440
|
-1.329
|
-1.102
|
-0.8548
|
-0.8517
|
-0.4767
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/2/22
|
8/9/22
|
11/7/22
|
2/27/23
|
5/9/23
|
8/7/23
|
11/6/23
|
2/20/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
200
|
136
|
37.4
|
107
|
208
|
46.3
|
72.2
|
592
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.4
|
-78.5
|
-109
|
-117
|
-146
|
-191
|
-45
|
191
|
ROE (net income / shareholders' equity)
|
-
|
-69.5%
|
-202%
|
-299%
|
-159%
|
-173%
|
55.2%
|
89.5%
|
ROA (Net income/ Total Assets)
|
-57.9%
|
-
|
-95.2%
|
-89.3%
|
-
|
-
|
-
|
-
|
Assets
1 |
118
|
-
|
137
|
209.6
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.840
|
3.040
|
0.4200
|
2.520
|
4.030
|
0.6400
|
3.930
|
13.90
|
Cash Flow per Share
2 |
-
|
-2.110
|
-2.880
|
-2.870
|
-3.190
|
-5.090
|
0.3900
|
-
|
Capex
1 |
0.02
|
0.05
|
0.31
|
0.7
|
0.58
|
0.61
|
0.86
|
1.16
|
Capex / Sales
|
-
|
-
|
-
|
1.4%
|
0.22%
|
0.16%
|
0.13%
|
0.1%
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Last Close Price
72.5
USD Average target price
123.6
USD Spread / Average Target +70.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.91% | 3.44B | | -2.35% | 89.08B | | +3.55% | 40.9B | | -14.40% | 32.25B | | +55.89% | 25.14B | | -15.96% | 15.39B | | -15.50% | 11.91B | | -41.29% | 11.89B | | -11.75% | 11.64B | | +7.87% | 9.03B |
Biopharmaceuticals
|